$3.61
2.27% today
Nasdaq, Oct 31, 09:00 pm CET
ISIN
US92511W1080
Symbol
VRCA

Verrica Pharmaceuticals Inc Stock price

$3.61
-0.70 16.24% 1M
-1.03 22.23% 6M
-3.39 48.43% YTD
-10.39 74.21% 1Y
-21.29 85.50% 3Y
-71.29 95.18% 5Y
-171.39 97.94% 10Y
-171.39 97.94% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
+0.08 2.27%
ISIN
US92511W1080
Symbol
VRCA
Industry

Key metrics

Basic
Market capitalization
$33.3m
Enterprise Value
$56.1m
Net debt
$22.8m
Cash
$15.4m
Shares outstanding
9.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.3 | 1.0
EV/Sales
3.8 | 1.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-18.2%
Return on Equity
776.7%
ROCE
-391.7%
ROIC
-
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$14.7m | $32.7m
EBITDA
$-38.2m | $-31.5m
EBIT
$-38.7m | $-15.1m
Net Income
$-48.6m | $-12.0m
Free Cash Flow
$-47.4m
Growth (TTM | estimate)
Revenue
5.7% | 332.2%
EBITDA
52.2% | 51.4%
EBIT
52.1% | 77.1%
Net Income
44.1% | 84.3%
Free Cash Flow
28.2%
Margin (TTM | estimate)
Gross
86.5%
EBITDA
-259.7% | -96.3%
EBIT
-263.4%
Net
-330.5% | -36.8%
Free Cash Flow
-322.1%
More
EPS
$-5.1
FCF per Share
$-5.1
Short interest
5.7%
Employees
71
Rev per Employee
$110.0k
Show more

Is Verrica Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Verrica Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

Buy
64%
Hold
36%

Financial data from Verrica Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15 15
6% 6%
100%
- Direct Costs 1.99 1.99
10% 10%
14%
13 13
9% 9%
86%
- Selling and Administrative Expenses 44 44
38% 38%
297%
- Research and Development Expense 7.70 7.70
62% 62%
52%
-38 -38
52% 52%
-260%
- Depreciation and Amortization 0.55 0.55
42% 42%
4%
EBIT (Operating Income) EBIT -39 -39
52% 52%
-263%
Net Profit -49 -49
44% 44%
-331%

In millions USD.

Don't miss a Thing! We will send you all news about Verrica Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verrica Pharmaceuticals Inc Stock News

Neutral
Business Wire
7 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) breached their fiduciary duties to shareholders. If you currently own Verrica stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court...
Neutral
GlobeNewsWire
11 days ago
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH ® in the EU and that no additional Phase 3 studies are required –
Neutral
GlobeNewsWire
24 days ago
WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at...
More Verrica Pharmaceuticals Inc News

Company Profile

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Head office United States
CEO Jayson Rieger
Employees 71
Founded 2013
Website verrica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today